Pancreatic cancer is notoriously aggressive, characterized by its dense, fibrotic tumor microenvironment and a high propensity for metastasis, particularly to the liver. The IU team, led by Dr. Melissa L. Fishel, PhD, focused on fibrinogen, a critical component of blood clot formation that is converted into fibrin following vascular injury. Their research discovered that fibrinogen accumulates within pancreatic tumors, contributing structurally and biochemically to the tumor milieu, facilitating tumor growth and influencing the cancer cells’ behavior.

Dr. Fishel explained that pancreatic cancer patients frequently exhibit elevated rates of thrombotic events, such as deep-vein thrombosis (DVT). This observation prompted the team to investigate whether coagulation factors like fibrinogen were merely bystanders or active contributors to cancer progression. Through sophisticated genetic and biochemical techniques to reduce fibrinogen levels in mouse models, the researchers were able to demonstrate a clear causal link: tumors in mice with depleted fibrinogen showed marked reductions in primary tumor size and a dramatic decrease in liver metastases.

The study utilized multiple tumor cell lines, including patient-derived models developed by the cancer center’s Pancreatic Cancer Working Group. These models more closely mimic the heterogeneity and complexity of human pancreatic tumors, providing robust evidence that the effect of fibrinogen depletion is broadly applicable rather than tumor type-specific. Importantly, while fibrinogen depletion impaired tumor growth in the pancreas, it did not affect metastatic tumor growth once tumor cells had colonized secondary sites like the liver or lungs, suggesting that fibrinogen’s impact is localized to the primary tumor microenvironment.

A striking aspect of the study is the demonstration that fibrinogen’s presence within the pancreatic tumor microenvironment orchestrates key aspects of cancer-associated fibroblast activity and extracellular matrix remodeling. These fibroblasts are instrumental in constructing a protumorigenic niche that nurtures cancer cells, promotes immune evasion, and fosters treatment resistance. By reducing fibrinogen, the researchers suppressed fibroblast recruitment and matrix deposition, effectively dismantling the scaffolding that supports tumor growth and dissemination.

Despite these promising findings, Dr. Fishel stresses the importance of a balanced therapeutic approach. Fibrinogen is critical for normal hemostasis, and its complete elimination could provoke excessive bleeding and other severe complications. Instead, the goal is to normalize fibrinogen levels in pancreatic cancer patients—lowering them from pathologically high concentrations back to baseline, a strategy presumed to be clinically manageable without compromising patient safety.

The research team is now focused on deciphering the molecular signaling pathways modulated by fibrinogen within the tumor microenvironment. Understanding the downstream effectors influenced by fibrin will be pivotal for developing combination therapies that target both the clotting axis and cancer cell vulnerabilities. Such combination strategies hold the promise of enhancing the efficacy of existing chemotherapeutics and novel targeted agents, potentially transforming the clinical management of pancreatic cancer.

This study emerges from the Pancreatic Cancer Stromal Reprogramming Consortium, a national collaborative network dedicated to accelerating discoveries in stromal biology and tumor microenvironment modulation. The consortium’s integrated approach brings together experts from multiple disciplines and institutions to tackle the complexity of pancreatic cancer, a cancer type with traditionally poor prognosis and limited responsiveness to conventional therapies.

Contributing significantly to this research, postdoctoral fellow Nayela N. Chowdhury served as the study’s first author, with additional support from colleagues Dana K. Mitchell, Silpa Gampala, Kylee Brewster, Wade Clapp, and Jia Wang. The IU School of Medicine, recognized for its leadership in medical research and ranked among the top U.S. medical schools, provided the robust scientific environment and resources necessary for such high-impact research.

The discovery that modulating a blood clotting protein within the tumor microenvironment can affect pancreatic cancer progression fundamentally shifts how researchers understand tumor biology and metastasis. It highlights the intricate relationship between cancer and systemic physiological processes like coagulation, offering new angles for intervention beyond traditional cytotoxic approaches.

In conclusion, this study represents a paradigm shift in pancreatic cancer research by illuminating the tumor-supportive role of fibrinogen. While not a standalone cure, fibrinogen-targeted therapy combined with current or emerging treatments could delay disease progression and improve patient outcomes. The next phase of this research will delve deeper into molecular mechanisms and clinical translation, aiming to transform these compelling preclinical insights into tangible benefits for patients.

Subject of Research: Role of fibrinogen in pancreatic ductal adenocarcinoma tumor growth and metastasis

Article Title: Depleting Liver-Derived Fibrinogen Slows Pancreatic Cancer Progression in Preclinical Models

News Publication Date: Not specified in article

Web References:

• Indiana University Melvin and Bren Simon Comprehensive Cancer Center: https://cancer.iu.edu/
• IU School of Medicine: https://medicine.iu.edu/
• Gastroenterology journal DOI: https://doi.org/10.1053/j.gastro.2025.09.024
• Pancreatic Cancer Stromal Reprogramming Consortium: https://www.nci-psrc.org/

References:
Fishel ML et al. (2025). Study on fibrinogen depletion in PDAC models. Gastroenterology.

Image Credits: Tim Yates, IU School of Medicine

Keywords: Pancreatic cancer, fibrinogen, blood clotting proteins, tumor microenvironment, metastasis, pancreatic ductal adenocarcinoma, cancer-associated fibroblasts, thromboembolism, deep-vein thrombosis, tumor progression, liver metastases, cancer biology

C-Rel is a member of the NF-kB family of transcription factors, which are crucial in regulating immune responses, cell survival, and proliferation. It has garnered attention for its role in various malignancies. However, its specific function in pancreatic cancer metastasis was not well understood until now. The researchers embarked on an exhaustive study to delineate the mechanisms by which c-Rel promotes the aggressive nature of pancreatic cancer cells. They employed a variety of cell models, animal studies, and advanced molecular techniques to unveil the multifaceted role of c-Rel in pancreatic cancer progression.

A significant aspect of their findings relates to the interaction between c-Rel and fibronectin-integrin signaling pathways. Fibronectin is a glycoprotein that plays an integral role in cell adhesion, migration, and survival. Integrins, on the other hand, are transmembrane receptors that mediate these fibronectin interactions. The authors hypothesized that the c-Rel protein interacts with this signaling axis to enhance the survival of pancreatic cancer cells under stress, a phenomenon they termed “isolation stress resistance.” This discovery suggests that c-Rel not only drives aggressive growth but also equips cancer cells with the ability to evade the detrimental effects of nutrient deprivation and adverse microenvironments.

The researchers further explored the concept of epithelial-mesenchymal transition (EMT), a critical process in cancer progression that allows epithelial cells to acquire migratory and invasive capabilities. The study revealed that c-Rel facilitates EMT in pancreatic cancer cells, thereby promoting their metastatic potential. By regulating the expression of various downstream genes associated with the EMT process, c-Rel appears to drive the transformation of pancreatic cells into a more aggressive phenotype capable of dissemination throughout the body. This connection between c-Rel, fibronectin-integrin signaling, and EMT underscores the complexity of cancer biology and the interplay of multiple pathways in tumor progression.

One of the striking aspects of this research is the potential for targeting c-Rel in therapeutic strategies. As a critical player in the metastatic cascade, c-Rel presents an attractive target for drug development. The ability to inhibit its function may hinder the metastatic spread of pancreatic cancer and improve treatment outcomes for patients. The authors propose that small molecules or monoclonal antibodies designed to disrupt the c-Rel signaling axis could be explored as novel treatment options. Such therapies could aim to reduce both the tumor’s invasive capabilities and its ability to survive in adverse conditions.

The implications of this research extend beyond the confines of pancreatic cancer. Understanding the mechanisms of c-Rel-mediated metastasis could enhance our overall knowledge of cancer biology and provide insights that are applicable to other malignancies exhibiting similar aggressive behaviors. By elucidating shared pathways across various cancers, researchers may identify common therapeutic targets that could lead to broader treatment paradigms.

While the findings are promising, there remain considerable challenges in translating these discoveries into clinical practice. The intricate signaling networks involved in cancer metastasis are not only complex but also highly context-dependent. Further research is needed to delineate the specific interactions between c-Rel and other molecular players within the tumor microenvironment. Additionally, elucidating how these findings translate to human disease will require the development of sophisticated experimental models and early-phase clinical trials.

In conclusion, the work of Bakırdöğen and colleagues provides a significant step forward in understanding the molecular underpinnings of pancreatic cancer metastasis. Their investigation into the role of c-Rel in modulating fibronectin-integrin signaling and promoting isolation stress resistance and EMT opens new avenues for therapeutic intervention. As we continue to unravel the complexities of cancer biology, such insights are critical for developing more effective and targeted treatment modalities aimed at improving patient outcomes.

The journey from molecular discovery to clinical application is often fraught with challenges, but with ongoing research and innovation, the hope remains that we can unveil new strategies to combat pancreatic cancer and offer patients a glimmer of hope in the face of one of the deadliest diseases.

Subject of Research: Role of c-Rel in pancreatic cancer metastasis and its implications for treatment.

Article Title: c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT.

Article References:
Bakırdöğen, D., Görgülü, K., Xin, J. et al. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT.
Mol Cancer (2025). https://doi.org/10.1186/s12943-025-02486-5

Image Credits: AI Generated

DOI:

Keywords: pancreatic cancer, c-Rel, metastasis, fibronectin-integrin signaling, epithelial-mesenchymal transition, cancer biology, therapeutic targets.